A sensitive screening strategy that improves patient compliance.
A screening strategy that’s simple for healthcare providers to order and easy for patients to use.
*92% sensitivity‡4 in detecting colorectal cancers, stages I-IV. 87% specificity overall§4, excluding colorectal cancer and advanced adenomas. 68% compliance‖ with Cologuard.
†Stool DNA (i.e. Cologuard) is one of the methods permitted as part of NCQA’s HEDIS® quality measures for colon cancer screening. Third party guidelines and quality measures do not specifically “endorse” commercial products, and inclusion in same does not imply otherwise.
‡Cologuard sensitivity, per stage of cancer: I: 90% (n = 29); II: 100% (n = 21); III: 90% (n = 10); IV: 75% (n = 4).5
§Cologuard specificity: 87% overall specificity excluding colorectal cancer and advanced adenoma; and including all nonadvanced adenomas, non-neoplastic findings, and negative results on colonoscopy. 90% specificity in participants with no lesions biopsied on colonoscopy.5
‖Internal data. Exact Sciences Laboratories. Cologuard's compliance rate represents the cumulative completed tests from kits shipped to patients during the six-month period ending 12 months prior to the end of the most recent quarter reported, excluding program orders.
1. Bibbins-Domingo K, Grossman DC, Curry SJ, et al; for US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(23):2564-2575.
2. American Cancer Society. American Cancer Society guidelines for early detection of cancer. Revised May 30, 2018. Accessed August 14, 2018.
3. National Committee for Quality Assurance website. HEDIS 2017 Volume 2 Technical Update. Accessed August 14, 2018.
4 Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014 Apr 3;370(14):1287-1297.
5 American Cancer Society. Cancer Facts & Figures 2017. American Cancer Society website. Accessed August 14, 2018.